Jeffrey Newcorn Selected Research

carboranyl oligophosphate CB10

12/2009

Stimulant drug response in the predominantly inattentive and combined subtypes of attention-deficit/hyperactivity disorder.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jeffrey Newcorn Research Topics

Disease

13	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2021 - 11/2002
2	Substance-Related Disorders (Drug Abuse) 01/2019 - 08/2007
2	Confusion (Bewilderment) 07/2008 - 07/2008
1	Separation Anxiety (Separation Anxiety Disorder) 09/2007
1	Anxiety Disorders (Anxiety Disorder) 09/2007
1	Social Phobia 09/2007

Drug/Important Bio-Agent (IBA)

4	Pharmaceutical PreparationsIBA 01/2019 - 02/2007
4	Methylphenidate (Ritalin)FDA LinkGeneric 01/2016 - 01/2006
3	Pemetrexed (MTA)FDA Link 07/2008 - 11/2004
2	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA 06/2014 - 02/2007
2	Atomoxetine Hydrochloride (Strattera)FDA LinkGeneric 09/2007 - 11/2002
2	Dopamine (Intropin)FDA LinkGeneric 08/2007 - 02/2007
1	metadoxineIBA 01/2021
1	TabletsIBA 01/2016
1	Dexmethylphenidate Hydrochloride FDA LinkGeneric 06/2014
1	Amphetamine (Amfetamine)FDA LinkGeneric 06/2014
1	SaltsIBA 06/2014
1	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 12/2009
1	carboranyl oligophosphate CB10IBA 12/2009
1	CarbonIBA 08/2007
1	RacloprideIBA 08/2007
1	Cocaine (Cocaine HCl)IBA 02/2007

Therapy/Procedure

3	Combined Modality Therapy 07/2008 - 11/2004
2	Therapeutics 07/2008 - 07/2008